At least one serious adverse event during the safety surveillance period was reported by 1323 ( 8.3 % ) of the participants in the IIV3-HD group , as compared with 1442 ( 9.0 % ) of the participants in the IIV3-SD group ( relative risk , 0.92 ; 95 % CI , 0.85 to 0.99 ) .